Press Releases Lineage Cell Therapeutics, Inc.

Equities

LCTX

US53566P1093

Market Closed - Nyse Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
1.09 ^USD	-2.68%		-4.39%	-.--%

Apr. 29	Lineage Cell Therapeutics, Inc. Announces Changes to Board of Directors	CI
Mar. 11	Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lineage Cell Therapeutics : Immediate Report	Apr. 30	PU
Lineage Cell Therapeutics : Additional proxy soliciting materials - definitive	Apr. 30	PU
Lineage Cell Therapeutics : NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 11, 2024, PROXY	Apr. 30	PU
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)	Apr. 30	BU
Lineage Announces Changes to Board of Directors	Apr. 29	BU
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development	Apr. 01	BU
Lineage Cell Therapeutics : Immediate Report	Mar. 24	PU
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium	Mar. 18	BU
LINEAGE CELL THERAPEUTICS, INC. - RG6501 PHASE 1/2A CLINICAL STUDY 24 MONTH RESULTS TO BE FEATURED AT 2024 RETINAL CELL AND GENE THERAPY INNOVATION SUMMIT	Mar. 14	AQ
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit	Mar. 13	BU
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting	Mar. 11	BU
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Samuel George A. III	Mar. 10	PU
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP- Cukkey Brian M	Mar. 10	PU
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Howe Jill Ann	Mar. 10	PU
Lineage Cell Therapeutics : FORM S-3-Registration Statements	Mar. 10	PU
Lineage Cell Therapeutics : Annual report which provides a comprehensive overview of the company for the past year	Mar. 10	PU
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 07	BU
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024	Feb. 29	BU
Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury	Feb. 13	BU
LINEAGE CELL THERAPEUTICS ANNOUNCES CLOSING OF $14.0 MILLION REGISTERED DIRECT OFFERING	Feb. 12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Lineage Cell Therapeutics, Inc.

Equities

LCTX

US53566P1093

Press Releases

Filters